Alerts will be sent to your verified email
Verify Email
GLAXO
Insufficient data
Positive for this company
Neutral for this company
Negative for this company
Insufficient data to analyse
Glaxosmithkline Pharmaceuticals Limited offers a broad range of medicines and vaccines with commercial leadership in anti-infectives and dermatology, focusing on immune science, genetics, and advanced technologies. They are leaders in the private segment in India.
Glaxosmithkline Phar major competitors are Glenmark Pharma, Ipca Laboratories, Aurobindo Pharma, Ajanta Pharma, Alkem Laboratories, Gland Pharma, Abbott India.
Market Cap of Glaxosmithkline Phar is ₹47,511 Crs.
While the median market cap of its peers are ₹54,414 Crs.
Glaxosmithkline Phar seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Annual Report | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | ||
| Earnings Release | May | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Jun Sep | Mar Jun Sep Dec | Mar Jun Sep Dec | Mar Jun Sep Dec | Jun Sep | Mar Jun Sep Dec | Dec | |||||||
| Investor Presentation | May Aug | Mar Jun | Jun | Jun | Dec | Mar | ||||||||||||
| Conference Call | Mar Jun | Mar Jun Sep Dec | Dec | Jun Sep | ||||||||||||||
|
Conference Call SummaryCon Call Summary
Powered by Gemini
|
